Testing a drug given two ways for cancer spread to the lining of the brain
Original title: Combined Intrathecal and Systemic Therapy With Trastuzumab Rezetecan for Leptomeningeal Metastases
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is a middle stage study, so the drug is still being tested in people.
Status: Not yet recruiting. It has not opened yet. Ask your care team to watch for it if it looks like a fit.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This study tests a drug called Trastuzumab Rezetecan for cancer that has spread to the fluid and lining around the brain and spine.
Who this trial is for. This trial is for people whose solid tumor cancer has spread to the leptomeninges, the thin layers that cover the brain and spinal cord. Everyone in the study gets Trastuzumab Rezetecan two ways: into the spinal fluid and into the bloodstream.
Where it stands. The trial has not reported results. The team wants to learn how well this drug works and how safe it is when given both ways. That answer is not in yet.
What this means, and what it doesn't
What it could mean: This type of spread is hard to treat, and the study is looking for another option. If this sounds like your situation, you could ask your care team about it. They can tell you if a study like this makes sense for you.
What it doesn't mean: This does not mean the drug works. A trial is a test, not a proven treatment. Joining a study does not promise that you will be helped. This is not a cure, and no one can say yet if it helps people live longer or feel better.
Source: ClinicalTrials.gov, September 22, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.